December 6, 2025MedCommOpen Access

Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Innovative assay predicts recurrence in solid tumors using circulating tumor DNA, indicating enhanced clinical decision-making.

The ctDNA assay predicted postoperative recurrence up to 112 days earlier for breast cancer, demonstrating its high sensitivity.
Clinically relevant genomic profiling helps to inform personalized monitoring for minimal residual disease across tumor types.
This novel approach to monitoring utilizes a highly specific assay for effective prognostic stratification of patients.
Clinical decision-making is improved by early detection with a limit of detection as low as 0.005% for circulating tumor DNA.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 6, 2025MedCommOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Innovative assay predicts recurrence in solid tumors using circulating tumor DNA, indicating enhanced clinical decision-making.

The ctDNA assay predicted postoperative recurrence up to 112 days earlier for breast cancer, demonstrating its high sensitivity.
Clinically relevant genomic profiling helps to inform personalized monitoring for minimal residual disease across tumor types.
This novel approach to monitoring utilizes a highly specific assay for effective prognostic stratification of patients.
Clinical decision-making is improved by early detection with a limit of detection as low as 0.005% for circulating tumor DNA.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark